Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Abbisko Cayman Limited ( (HK:2256) ) has provided an update.
Abbisko Cayman Limited has completed a placing of 42,900,000 new shares under its general mandate at HK$12.18 per share, with all shares subscribed by at least six independent investors who will not become substantial shareholders. The enlarged share capital increases the company’s issued shares by about 5.99%, modestly diluting existing holdings while broadening its investor base.
The placing raised gross proceeds of approximately HK$522.5 million, with net proceeds of around HK$517.3 million after fees and expenses. Abbisko plans to allocate roughly 90% of the funds to advance R&D for oncology and non-oncology drug candidates, international multi-centre clinical trials and commercialization efforts, with the remaining 10% for general corporate use, strengthening its financial capacity to execute its pipeline strategy.
The most recent analyst rating on (HK:2256) stock is a Buy with a HK$27.10 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.
More about Abbisko Cayman Limited
Abbisko Cayman Limited is a biopharmaceutical company focused on the research and development of innovative oncology and non-oncology drug candidates. The company pursues international multi-centre clinical trials and is preparing for potential commercialization activities in global pharmaceutical markets.
Average Trading Volume: 1,874,686
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.25B
For detailed information about 2256 stock, go to TipRanks’ Stock Analysis page.